Electronic Nose and Fetal Chromosomal Disorders

Overview

"electronic nose"- the tiny sensors, will smell and detect the changes in the sample of abnormal fetal karyotype, and fluid that will be confirmed by amniocentesis.

Full Title of Study: “Examining the Ability of Electronic Nose in Detecting Fetal Chromosomal Disorders”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: August 2017

Detailed Description

The biochemical engineering department had developed a device called "electronic nose" that can detect various diseases Including cancer and asthma on basis of evaporable substances. The device simulates the human nose ", which includes an array of tiny sensors connected to nanometric sizes electronic calculating unit.. Thanks to their small size, electrical, physical and chemical properties, the sensitive sensors smell and identified changes in composition of the materials that characterize various diseases including kidney disease and asthma. The electronic nose was developed by Professor Haick from the Technion. The main concept of the device is testing and characterization a trace amounts of substances in the air with the help of nana-technology sensors the idea is revolutionary and would allow the diagnosis of different diseases, like cancer, by exhaling air into the device. The test is simple and not complicated to perform ,the examiner inhale air into a bag which connected to the "electronic nose". The molecules of the patient's breath will be tied to sensors and transmit an electrical signal to computer chip. After processing the data the "electronic nose "can distinguish between normal cells and pathological cells. Hypothesis: the tiny sensors ("electronic nose") will smell and detect the changes in the sample of abnormal fetal karyotype, and fluid that will be confirmed by amniocentesis.

Interventions

  • Other: observational study done only in women candidate for amniocentesis
    • As a part of routine test in women with obstetrical indication for amniocentesis, we take 30 cc of amniotic fluid. only additional 3 ml of the amniotic fluid are needed for examination by electronic sensors.

Arms, Groups and Cohorts

  • women candidates for amniocentesis
    • pregnant women candidates for amniocentesis between 17-33 gestational weeks

Clinical Trial Outcome Measures

Primary Measures

  • Examining the ability of the electronic nose in detecting abnormal fetal karyotype
    • Time Frame: 3 years
    • the electronic nose can detect various diseases Including cancer and asthma on basis of evaporable substances. The device simulates the human nose “, which includes an array of tiny sensors connected to nanometric sizes electronic calculating unit. 30 cc of amniotic fluid are part of routine tests and the rest of the amount (3 ml) is intended for research, this sample will be saved in cooling (-20) and subsequently transferred to the Technion, for examination by electronic sensors. The amount of amniotic fluid designed for research is a minimal amount and will not hurt the fetus. At the end of the study following the data processing, we will be able to appreciate the effectiveness of the electronic nose in diagnosing fetal chromosomal disorders.

Participating in This Clinical Trial

Inclusion Criteria

  • Pregnant women candidates for amniocentesis – 17-33 gestational weeks Exclusion Criteria:

  • women that refuse to participate in the research – women older than 45 or less than 16

Gender Eligibility: Female

Minimum Age: 16 Years

Maximum Age: 45 Years

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • Rambam Health Care Campus
  • Provider of Information About this Clinical Study
    • Sponsor

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.